Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL703953 | 0.89 | NR1H2 (0.40) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL21730405 | 0.89 | NR1H2 (0.34) | NR1H2DPP4HDAC8CHRM2CHRM1 | |
| SCHEMBL26922100 | 0.89 | NR1H2 (0.34) | NR1H2DPP4HDAC8CHRM2CHRM1 | |
| SCHEMBL703952 | 0.89 | NR1H2 (0.40) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL19540623 | 0.89 | NR1H2 (0.34) | NR1H2DPP4HDAC8CHRM2CHRM1 | |
| SCHEMBL19127641 | 0.89 | NR1H2 (0.34) | NR1H2DPP4HDAC8CHRM2CHRM1 | |
| SCHEMBL17001728 | 0.89 | NR1H2 (0.40) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL15321300 | 0.87 | HSD17B10 (0.33) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL33526043 | 0.87 | HSD17B10 (0.33) | NR1H2HDAC8CHRM2CHRM1CHRM3 | |
| SCHEMBL18382131 | 0.87 | CASP3 (0.34) | NR1H2HDAC8CETPCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | NR1H2 176/4885DPP4 4642/4885HDAC8 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.